The Future of Noninvasive Multi-Cancer Screening

contributed by Horizon Discovery | 04/06/2023

A revolutionary development in the oncology field is the emergence of technologies that enable clinicians to rapidly screen for multiple cancer types using a single blood sample.

These tests, known as multi-cancer early detection (MCED) tests, are designed to detect circulating tumor biomarkers in the blood. And improve early detection, treatment, and outcomes for cancer patients.

Our latest whitepaper summarizes discussions between a panel of industry and academic leaders about the challenges and opportunities of MCED tests.

Download Full Whitepaper

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.